We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TAK or DSNKY: Which Is the Better Value Stock Right Now?
Read MoreHide Full Article
Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co. (TAK - Free Report) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Currently, Takeda Pharmaceutical Co. has a Zacks Rank of #2 (Buy), while Daiichi Sankyo Co., Ltd. - Sponsored ADR has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that TAK likely has seen a stronger improvement to its earnings outlook than DSNKY has recently. However, value investors will care about much more than just this.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
TAK currently has a forward P/E ratio of 9.49, while DSNKY has a forward P/E of 31.25. We also note that TAK has a PEG ratio of 0.27. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. DSNKY currently has a PEG ratio of 1.80.
Another notable valuation metric for TAK is its P/B ratio of 0.98. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, DSNKY has a P/B of 4.20.
Based on these metrics and many more, TAK holds a Value grade of A, while DSNKY has a Value grade of C.
TAK stands above DSNKY thanks to its solid earnings outlook, and based on these valuation figures, we also feel that TAK is the superior value option right now.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TAK or DSNKY: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co. (TAK - Free Report) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Currently, Takeda Pharmaceutical Co. has a Zacks Rank of #2 (Buy), while Daiichi Sankyo Co., Ltd. - Sponsored ADR has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that TAK likely has seen a stronger improvement to its earnings outlook than DSNKY has recently. However, value investors will care about much more than just this.
Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
TAK currently has a forward P/E ratio of 9.49, while DSNKY has a forward P/E of 31.25. We also note that TAK has a PEG ratio of 0.27. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. DSNKY currently has a PEG ratio of 1.80.
Another notable valuation metric for TAK is its P/B ratio of 0.98. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, DSNKY has a P/B of 4.20.
Based on these metrics and many more, TAK holds a Value grade of A, while DSNKY has a Value grade of C.
TAK stands above DSNKY thanks to its solid earnings outlook, and based on these valuation figures, we also feel that TAK is the superior value option right now.